Related Articles
Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility
Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)
Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non‑small cell lung cancer
ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma